Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

PURPOSE: Angiogenesis plays a pivotal role in tumor growth and metastasis. Sorafenib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR), combined with bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF-A), would vertically inhibit VEGF/VEG...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Falchook, Gerald S., Wheler, Jennifer J., Naing, Aung, Piha-Paul, Sarina A., Fu, Siqing, Tsimberidou, Apostolia M., Hong, David S., Janku, Filip, Zinner, Ralph, Jiang, Yunfang, Huang, Mei, Lin, Quan, Parkhurst, Kristin, Kurzrock, Razelle
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4477529/
https://ncbi.nlm.nih.gov/pubmed/25363205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0176-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky